# Boswellin PS (Boswellia serrata)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/boswellin-ps
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Boswellia serrata, Indian frankincense, Salai guggal, Salai gugul, Shallaki, Indian olibanum, Boswellia extract, Frankincense extract, Boswellic acids extract

## Overview

Boswellin PS is a phosphatidylserine-complexed extract of Boswellia serrata standardized to boswellic acids, particularly acetyl-11-keto-β-boswellic acid (AKBA), which inhibits 5-lipoxygenase (5-LOX) to reduce leukotriene B4 synthesis. This targeted enzyme inhibition differentiates it from standard Boswellia extracts by potentially enhancing bioavailability of AKBA through the phospholipid carrier matrix.

## Health Benefits

• [Anti-inflammatory](/ingredients/condition/inflammation) effects through inhibition of 5-lipoxygenase and reduction of inflammatory mediators (in-vitro evidence only)
• Potential joint health support via reduction of LTB4 and PGE2 production (IC50 6.19 μg/mL for PGE2 in cell studies)
• May support inflammatory conditions based on traditional Ayurvedic use (traditional evidence only)
• Possible gastric health benefits per historical use (traditional evidence only)
• Potential arthritis support based on centuries of Ayurvedic application (traditional evidence only)

## Mechanism of Action

Boswellin PS exerts [anti-inflammatory](/ingredients/condition/inflammation) effects primarily through AKBA-mediated inhibition of 5-lipoxygenase (5-LOX), blocking the conversion of arachidonic acid to pro-inflammatory leukotriene B4 (LTB4). It also suppresses prostaglandin E2 (PGE2) production, with an IC50 of approximately 6.19 μg/mL demonstrated in cell-based assays, reducing downstream COX-pathway signaling. The phosphatidylserine complexation is theorized to enhance lymphatic absorption of AKBA, circumventing first-pass hepatic [metabolism](/ingredients/condition/weight-management) and improving systemic delivery of active boswellic acids.

## Clinical Summary

Most mechanistic evidence for Boswellin PS specifically comes from in-vitro cell studies demonstrating inhibition of LTB4 and PGE2, rather than large randomized controlled trials on the phosphatidylserine-complexed form itself. Broader Boswellia serrata research includes randomized trials in osteoarthritis populations — notably a 2003 study by Kimmatkar et al. (n=30) showing statistically significant reductions in knee pain and improved function versus placebo over 8 weeks. A 2011 study using a 100 mg AKBA-standardized extract (n=60) reported significant improvements in pain and physical function scores after 90 days. Evidence for the specific Boswellin PS phosphatidylserine-complexed formulation in human clinical trials remains limited, and efficacy data should be interpreted cautiously pending formulation-specific research.

## Nutritional Profile

Boswellin PS is a standardized phosphatidylserine-complexed extract of Boswellia serrata resin, not a conventional food ingredient, so macronutrient and micronutrient profiles are not applicable in the traditional sense. Primary bioactive compounds are boswellic acids, typically standardized to ≥65% total boswellic acids by weight in PS-complexed form. Key boswellic acid constituents include: 11-keto-β-boswellic acid (KBA, ~6–8% of extract), acetyl-11-keto-β-boswellic acid (AKBA, ~3–5% of extract, considered most pharmacologically active), α-boswellic acid, β-boswellic acid, acetyl-α-boswellic acid, and acetyl-β-boswellic acid collectively comprising the remaining boswellic acid fraction. The phosphatidylserine (PS) complexation is specifically designed to enhance lipophilic boswellic acid bioavailability, as native boswellic acids have poor oral bioavailability due to low aqueous solubility; PS complexation is reported to improve absorption compared to standard resin extracts, though precise pharmacokinetic enhancement data (fold-increase) are proprietary and not fully published. The resin matrix also contains triterpene alcohols (tirucallic acids), essential oils (trace, <1%), and small amounts of polysaccharides. No meaningful vitamin, mineral, dietary fiber, or conventional protein content is present at typical supplemental doses (100–400 mg/day). Fat content is negligible at supplemental doses. Standardization marker AKBA is the primary quality benchmark per industry standards.

## Dosage & Preparation

No clinically studied dosage ranges are available for Boswellin PS, as human trial data is absent. The extract is standardized to 35-50% total boswellic acids, 20-30% β-boswellic acids, and 10-12% AKBA, with 35-45% Polysal polysaccharides. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Boswellia serrata extracts are generally well-tolerated, with the most commonly reported adverse effects being mild gastrointestinal symptoms including nausea, diarrhea, and abdominal discomfort, typically at doses above 900 mg/day. Boswellic acids may inhibit CYP450 enzymes (particularly CYP3A4 and CYP2C8/9), raising potential interaction concerns with anticoagulants such as warfarin and immunosuppressants like tacrolimus. Due to insufficient safety data, use during pregnancy and lactation is not recommended. Individuals with known hypersensitivity to frankincense resin or related Burseraceae plants should avoid this supplement.

## Scientific Research

No human clinical trials, RCTs, or meta-analyses were found specifically for Boswellin PS in the research provided. Available evidence is limited to in-vitro studies showing boswellic acids inhibit PGE2 production in LPS-stimulated human PBMCs with an IC50 of 6.19 μg/mL.

## Historical & Cultural Context

Boswellia serrata (Salai guggal) oleo-gum-resin has been used in Ayurvedic traditional medicine in India for centuries for inflammatory conditions, arthritis, and gastric disorders. The resin has historical significance as an [anti-inflammatory](/ingredients/condition/inflammation) agent in Indian traditional medicine systems.

## Synergistic Combinations

Turmeric extract, Glucosamine, Chondroitin, MSM, Ginger extract

## Frequently Asked Questions

### What is the difference between Boswellin PS and regular Boswellia serrata extract?

Boswellin PS is a proprietary form of Boswellia serrata complexed with phosphatidylserine, a phospholipid intended to enhance the oral bioavailability of the key active compound AKBA (acetyl-11-keto-β-boswellic acid). Standard Boswellia extracts are typically standardized to total boswellic acids (often 65%) or AKBA (5–20%) without a phospholipid carrier. The phosphatidylserine matrix may improve lymphatic uptake of AKBA, though head-to-head bioavailability studies in humans comparing the two formulations are limited.

### What is the recommended dosage of Boswellin PS for joint health?

A commonly studied dosage range for Boswellia serrata extracts in joint health contexts is 100–400 mg per day of a standardized extract, often dosed 2–3 times daily. For the Boswellin PS phosphatidylserine-complexed form, typical manufacturer dosing is 100–200 mg daily, reflecting the theorized improved bioavailability of AKBA. Because formulation-specific dose-response data in humans are lacking, consultation with a healthcare provider is recommended before establishing a regimen.

### Does Boswellin PS interact with anti-inflammatory drugs like ibuprofen or naproxen?

Boswellic acids inhibit both 5-lipoxygenase and partially COX pathways, which mechanistically overlaps with NSAIDs like ibuprofen and naproxen that primarily inhibit COX-1 and COX-2. Combining Boswellin PS with NSAIDs could theoretically produce additive anti-inflammatory effects but may also compound gastrointestinal side effects such as mucosal irritation. No formal clinical drug interaction studies exist for the Boswellin PS formulation with NSAIDs specifically, so caution and physician oversight are advised when combining these agents.

### How long does it take for Boswellin PS to work for joint pain?

Human trials using standardized Boswellia serrata AKBA extracts have generally reported measurable reductions in joint pain and stiffness within 4 to 8 weeks of consistent daily use. A 2011 randomized controlled trial using a 100 mg AKBA-standardized extract found significant improvements in pain scores and physical function by week 4, with continued improvement through 90 days. Results for Boswellin PS specifically may differ due to its phosphatidylserine complexation, and individual response times can vary based on severity of inflammation and baseline joint health status.

### Is Boswellin PS safe to take long-term?

Long-term safety data for Boswellia serrata extracts in general suggest a favorable tolerability profile, with most studies conducted over periods of 8–16 weeks reporting only mild and transient gastrointestinal side effects. Chronic use beyond six months has not been well characterized in large controlled trials, and the phosphatidylserine-complexed Boswellin PS form lacks independent long-term safety studies. Individuals taking medications metabolized by CYP3A4 or CYP2C enzymes, such as warfarin or statins, should consult a physician before long-term supplementation due to potential enzyme inhibition by boswellic acids.

### What does the research evidence show about Boswellin PS effectiveness compared to placebo?

Boswellin PS has demonstrated anti-inflammatory activity in laboratory studies, showing inhibition of 5-lipoxygenase and reduction of inflammatory markers like LTB4 and PGE2 in cell-based models. However, most in-vitro evidence does not directly translate to human clinical outcomes, and more rigorous human trials are needed to establish definitive efficacy compared to placebo. The traditional use in Ayurvedic medicine provides historical support, but clinical evidence in humans remains limited.

### Who should avoid taking Boswellin PS, and are there specific health conditions that contraindicate its use?

Individuals with known allergies to Boswellia serrata or related plants should avoid Boswellin PS. Those with existing gastric ulcers or severe digestive conditions should consult a healthcare provider before use, as boswellia may affect gastric health. Pregnant and nursing women should seek medical guidance before supplementing, as safety data in these populations is limited.

### How does Boswellin PS absorption and bioavailability compare to other Boswellia extract forms?

Boswellin PS is a proprietary standardized extract designed for enhanced absorption and consistency compared to unstandardized boswellia preparations. The standardization ensures consistent levels of active boswellic acids across batches, which may improve bioavailability relative to whole plant powders. However, comparative bioavailability studies between Boswellin PS and other branded Boswellia extracts are limited in published literature.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*